Navigation Links
FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™
Date:12/13/2011

MOUNTAIN VIEW, Calif., Dec. 13, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend that ADASUVE™ (Staccato® loxapine) be approved for use as a single dose in 24 hours when used with the FDA recommended Risk Evaluation and Mitigation Strategy (REMS), for the treatment for agitation in patients with schizophrenia or bipolar mania.  The vote on this question was 9/8/1 (yes/no/abstain).

"We view the recommendations by the PDAC today as another step forward in the development of ADASUVE," stated Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals.  "We appreciate the Advisory Committee's recognition of agitation as a serious and underappreciated symptom of schizophrenia and bipolar disorder.  If approved, we believe ADASUVE represents a valuable treatment option for patients and physicians alike.  We look forward to continuing to work toward our goal of bringing ADASUVE to market in 2012."    

As previously announced, the ADASUVE NDA Prescription Drug User Fee Act (PDUFA) goal date is February 4, 2012.  In Europe, a Marketing Authorization Application (MAA) for ADASUVE is currently under review by the European Medicines Agency (EMA) and the application will follow the Centralized Procedure.

Summary of Advisory Committee Voting
The FDA takes the committee's advice into consideration as part of its review of a New Drug Application, but is not bound by an advisory committee's recommendations.  After reviewing and discussing the ADASUVE data, the committee voted on the following questions:

  • Does the committee conclude that ADASUVE (loxapine) inhalation powder has been shown to be effective as a treatment for agitation in patients with schizophrenia or bipolar mania?  The resulting vote was:  17/1/0 (yes/no/abstain).
  • Does the committee conclude that ADASUVE (loxapine) inhalation powder has been shown to be acceptably safe for use as a treatment for agitation in patients with schizophrenia or bipolar mania:
    • a.  When used in conjunction with the REMS proposed by the sponsor? The resulting vote was:  1/17/0 (yes/no/abstain).
    • b.  When used in conjunction with the REMS proposed by the FDA?  The resulting vote was:  5/12/1 (yes/no/abstain).
  • Does the committee conclude that ADASUVE (loxapine) inhalation powder would be acceptably safe for use as a single dose in 24 hours as a treatment for agitation in patients with schizophrenia or bipolar mania:
    • a.  When used in conjunction with the REMS proposed by FDA?  The resulting vote was:  11/5/2 (yes/no/abstain).
  • Does the committee conclude that ADASUVE (loxapine) inhalation powder should be approved for use as a single dose in 24 hours when used with the FDA recommended REMS, for the treatment for agitation in patients with schizophrenia or bipolar mania.  The resulting vote was:  9/8/1 (yes/no/abstain).

 

About Agitation
Agitation can occur in many people suffering from major psychiatric disorders, including schizophrenia, which affects approximately 2.4 million adults in the United States, and bipolar disorder, which affects approximately 5.7 million adults in the United States.  More than 90% of these people will experience agitation in their lifetime.  Agitation generally escalates over a short period of time with patients initially feeling uncomfortable, tense and restless.  As the agitation intensifies, their behavior appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated.  Agitation episodes are currently most often treated with antipsychotics and / or benzodiazepines in oral or intramuscular injection preparations.  However, there are no non-invasive therapies that work within 30 minutes to help agitated patients in need of treatment.

About ADASUVE (Staccato loxapine) and the Staccato System
ADASUVE is an anti-agitation product candidate that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia.  The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience.  Click here to see an animation of how the Staccato system works.  In clinical studies, ADASUVE has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies.  The ADASUVE NDA contains efficacy and safety data from more than 1,600 patients and subjects, who have been studied in thirteen different clinical trials.

About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted in August 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement
This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
4. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 According to ... Market by Product (Instruments, Reagents, Software), Technology (Immunoassay, ... Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021" ... at USD 60.22 Billion in 2016. This market ... 5.5% during the forecast period (2016-2021) to reach ...
(Date:12/2/2016)... 2016 In the first ever attempt to ... derived from C. sativa, the Hebrew University in Jerusalem, ... Federico II , the Universita` del Piemonte Orientale and ... integrated and unified inventory of phytocannabinoids of different botanical ... the remarkable chemical and structural diversity of phytocannabinoids. As ...
(Date:12/2/2016)... Lilly and Company (NYSE: LLY ) will ... financial guidance for 2016 on Thursday, December 15, 2016. ... day with the investment community and media to further ... call will begin at 10 a.m. ET. Investors, media ... of the conference call through a link that will ...
Breaking Medicine Technology:
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... "Pro3rd ... allow FCPX editors to create versatile lower third titles with just a few clicks ... Pro3rd Accents Volume 2 includes 30 lower third animations. Choose from various styles with ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
Breaking Medicine News(10 mins):